EU · Phase III · Myeloid neoplasms
EU Phase III myeloid neoplasms: sites, PIs and CROs
Bologna participated in 13 of 22 Phase III myeloid neoplasm trials. Alessandra Iurlo participated in six, with five other investigators also leading the myeloid neoplasm trial network. IQVIA and Parexel supported five programs each. Twenty-one trials are authorised.
Countries
Spain appears in 19 trials
Germany and France each participate in 18 trials. Germany carries the largest site footprint among the five leading countries.
Sites
Bologna participates in 13 trials
AP-HP, CHU Bordeaux, CHU Nice and Vall d’Hebron each participated in 12.
Investigators
Alessandra Iurlo leads with six trials
Five other investigators also participated in six Phase III myeloid neoplasm trials.
CROs
IQVIA and Parexel support five programs
Syneos Health supports four programs, followed by ICON and PPD with three each.
Active trial footprint
21 trials are authorised
Fifteen recruit in at least one EU country. The authorised trials span 1,527 sites and 7,189 planned participants, averaging 72.7 sites, 8.9 countries and 342 planned participants per trial.
Source: CTIS trial records and trial documents, reviewed 22 September 2026.